ABEONA THERAPEUTICS INC.
Close on Oct 19, 2026
- Market cap
- $251.58M
- P/E (TTM)
- –
- Dividend yield
- –
About Abeona Therapeutics
Pharmaceutical Preparations, SIC 2834
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing cell and gene therapies for life-threatening genetic diseases. The company's primary commercial product is ZEVASKYN (prademagene zamikeracel), an autologous cell-based gene-modified cellular sheet therapy developed to treat wounds in adult and pediatric patients suffering from recessive dystrophic epidermolysis bullosa. In addition to its lead therapy, the company develops adeno-associated virus-based gene therapies targeting ophthalmic conditions through its proprietary and licensed AIM capsid technology platform. Abeona serves patients with severe genetic conditions through partnerships with academic researchers, patient advocacy organizations, caregivers, and biotechnology firms.
The company operates a current Good Manufacturing Practices manufacturing facility in Cleveland, Ohio, which handles both clinical and commercial-scale production. Abeona distributes its primary treatment through a specialized network of qualified treatment centers across the United States, with four centers activated as of March 2026. Abeona Therapeutics maintains its principal executive offices in Cleveland, Ohio.
Summary of the business section of Abeona Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ABEONA THERAPEUTICS INC.
- Headquarters
- Cleveland, OH
- Address
- 6555 Carnegie Ave, 4th Floor 44103
- Phone
- (646) 813-4701
- Website
- www.abeonatherapeutics.com
- Employees
- 226, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Morristown, New Jersey
Stock & identifiers
- Ticker
- ABEO
- Exchange
- Nasdaq
- IPO date
- Sep 19, 1980
- Shares outstanding
- 57M, Aug 10, 2026
- Public float
- $273.25M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Aug 11, 2022; 1-for-25 reverse, Jul 5, 2022; 1-for-50 reverse, Nov 14, 2014; 1-for-50 reverse, Oct 24, 2014; 1-for-5 reverse, Jun 5, 2006; 1-for-20 reverse, Jun 18, 1998; 1-for-2 reverse, Apr 16, 1992
- SEC CIK
- 318306
- CUSIP
- 00289Y206
- ISIN
- US00289Y2063
- LEI
- 54930002Z8PIJRCB4576
- EIN
- 83-0221517
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Vishwas Seshadri | Chief Executive Officer, Director | 1,286,500 |
| Madhav Vasanthavada | Chief Commercial Officer | 285,721 |
| Brendan M. O'Malley | SVP, Chief Legal Officer | 421,226 |
| Joseph Walter Vazzano | Chief Financial Officer | 482,888 |
| Mark Alvino | Director | 62,065 |
| Leila Alland | Director | 162,614 |
| Christine Berni Silverstein | Director | 119,562 |
| Eric Crombez | Director | 37,313 |
| Keith A. Goldan | Director | 32,751 |
| Donald A. Wuchterl | Director | 167,935 |
| Michael Amoroso | Director | 217,779 |
| Faith L. Charles | Director | 176,407 |
| Bernhardt G. Zeiher | Director | 84,458 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.99M | $4.04M | $1.56M | $171 | – |
| FY2025 Peo | $3.99M | $4.04M | $1.56M | $171 | – |
| FY2024 | $3.51M | $3.99M | $1.45M | $181 | – |
| FY2024 Peo | $3.51M | $3.99M | $1.45M | $181 | – |
| FY2023 | $2.85M | $3.46M | $1.33M | $163 | – |
| FY2022 | $1.50M | $1.30M | $656.54K | $37 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, we had 226 full-time employees.”
Corporate history
Events identified from SEC filings